Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis

Clinical trial NCT07219121 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT07219121
Sponsor: Travere Therapeutics, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 4
Study type: INTERVENTIONAL

Proteinuria Immunoglobulin A (IgA) Nephropathy Focal Segmental Glomerulosclerosis Kidney Transplant

Start date: 2025-10-07
Primary completion: 2027-03-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.